stockrowGSK PLC Sponsored ADR
GSK Healthcare Drug Manufacturers General
GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024.
- Revenue
- +3.75%
- EPS
- −14.7%
- Free cash flow
- +62.4%
- Total debt
- +33.2%
Quarter to September 2026, against a year earlier
Follow GSK
Alert me
GSK PLC Sponsored ADR (GSK) Revenue
GSK PLC Sponsored ADR's revenue for fiscal 2025 was $43.1B, up 7.44% from $40.1B in fiscal 2024. Over the twelve months to 30 September 2026 it was $44.9B. Over the past ten years it has ranged from $36.3B (fiscal 2022) to $46.9B (fiscal 2021); the current reading is higher than 73% of that period. Revenue has risen for 3 consecutive fiscal years. GSK PLC Sponsored ADR ranks 11th of 18 Drug Manufacturers General companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $43.1B | 7.44% |
| FY2024 | $40.1B | 6.28% |
| FY2023 | $37.7B | 4.01% |
| FY2022 | $36.3B | (22.68%) |
| FY2021 | $46.9B | 7.14% |
| FY2020 | $43.8B | 1.58% |
| FY2019 | $43.1B | 4.77% |
| FY2018 | $41.1B | 5.75% |
| FY2017 | $38.9B | 2.93% |
| FY2016 | $37.8B | 3.33% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $12.0B | 5.90% |
| Jun 2026 | $11.3B | 9.78% |
| Mar 2026 | $10.3B | (10.02%) |
| Dec 2025 | $11.4B | (0.83%) |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| PFE Pfizer Inc. compare | $63.6B |
| AZN AstraZeneca PLC compare | $62.4B |
| SNY Sanofi compare | $59.1B |
| NVO Novo Nordisk A/S compare | $51.5B |
| BMY Bristol Myers Squibb Company compare | $50.0B |
| GSK GSK PLC Sponsored ADR | $44.9B |
| AMGN Amgen Inc. compare | $38.9B |
| GILD Gilead Sciences, Inc. compare | $31.0B |
| BIIB Biogen Inc. compare | $10.3B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on GSK
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement